ID

15262

Beschreibung

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany

Link

https://clinicaltrials.gov/ct2/show/NCT02419378

Stichworte

Versionen (4)
  1. 13.08.15 13.08.15 - Martin Dugas
  2. 23.05.16 23.05.16 -
  3. 24.05.16 24.05.16 -
  4. 28.05.16 28.05.16 -
Hochgeladen am

24. Mai 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0 Legacy
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Treatment deferral Multiple Sclerosis ALAIN01 NCT02419378

Englisch

Treatment deferral Multiple Sclerosis ALAIN01 NCT02419378

1 Formulare  
Criteria for Treatment deferral
Beschreibung

Criteria for Treatment deferral

Alias
UMLS CUI-1
C0087111
UMLS CUI-2
C0205421
Patient ID (derived)
Beschreibung

Patient ID (derived)

Datentyp

text

Alias
UMLS CUI [1]
C2348585
Visit Info
Beschreibung

Visit Info

Datentyp

text

Alias
UMLS CUI [1]
C0545082
Recent relapse of MS
Beschreibung

Recent relapse of MS

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0856120
Recent vaccination ≤ 6 weeks
Beschreibung

Recent vaccination ≤ 6 weeks

Datentyp

boolean

Alias
UMLS CUI [1]
C0042196
Malignancy, except basal skin cell carcinoma
Beschreibung

Malignancy, except basal skin cell carcinoma

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrands disease, DIC, fibrinogen deficiency, clotting factor deficiency)
Beschreibung

Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrands disease, DIC, fibrinogen deficiency, clotting factor deficiency)

Datentyp

boolean

Alias
UMLS CUI [1]
C3251812
Of childbearing potential with a positive urine or serum pregnancy test, pregnant, or lactating. A blood pregnancy test must have been performed within 3 days prior to the first treatment day. If performed on the same day, the result of a urine dipstick test may be used instead.
Beschreibung

Of childbearing potential with a positive urine or serum pregnancy test, pregnant, or lactating. A blood pregnancy test must have been performed within 3 days prior to the first treatment day. If performed on the same day, the result of a urine dipstick test may be used instead.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety
Beschreibung

Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety

Datentyp

boolean

Alias
UMLS CUI [1]
C0442893
Most recent platelet count < the LLN of the evaluating laboratory, or patients with suspicion of incipient ITP
Beschreibung

Most recent platelet count < the LLN of the evaluating laboratory, or patients with suspicion of incipient ITP

Datentyp

boolean

Alias
UMLS CUI [1]
C0040034
CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie, absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3); if abnormal cell count(s) subsequently rises above 50, eligibility may be reassessed
Beschreibung

CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie, absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3); if abnormal cell count(s) subsequently rises above 50, eligibility may be reassessed

Datentyp

boolean

Alias
UMLS CUI [1]
C0003323
UMLS CUI [2]
C2698600
UMLS CUI [3]
C2698589
Neutrophil cell count ≤1000 cells/microliter; if abnormal cell count subsequently rises above 1000 cells/microliter, eligibility may be reassessed
Beschreibung

Neutrophil cell count ≤1000 cells/microliter; if abnormal cell count subsequently rises above 1000 cells/microliter, eligibility may be reassessed

Datentyp

boolean

Alias
UMLS CUI [1]
C0853697
Any other illness or infection (latent or active) that, in the Investigator’s opinion, could be exacerbated by alemtuzumab
Beschreibung

Any other illness or infection (latent or active) that, in the Investigator’s opinion, could be exacerbated by alemtuzumab

Datentyp

boolean

Alias
UMLS CUI [1]
C3843746
Treatment with immunosuppressive or antineoplastic drugs
Beschreibung

Treatment with immunosuppressive or antineoplastic drugs

Datentyp

text

Alias
UMLS CUI [1]
C0021081
Is the patient free of the above listed deferral criteria?
Beschreibung

Is the patient free of the above listed deferral criteria?

Datentyp

boolean

Alias
UMLS CUI [1]
C0205421
Comment Treatment deferral
Beschreibung

Comment Treatment deferral

Datentyp

text

Alias
UMLS CUI [1,1]
C0205421
UMLS CUI [1,2]
C0947611
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Treatment deferral Multiple Sclerosis ALAIN01 NCT02419378

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Criteria for Treatment deferral
C0087111 (UMLS CUI-1)
C0205421 (UMLS CUI-2)
Patient ID (derived)
Item
Patient ID (derived)
text
C2348585 (UMLS CUI [1])
Visit
Item
Visit Info
text
C0545082 (UMLS CUI [1])
Multiple sclerosis relapse
Item
Recent relapse of MS
boolean
C0856120 (UMLS CUI [1,1])
Vaccination
Item
Recent vaccination ≤ 6 weeks
boolean
C0042196 (UMLS CUI [1])
Malignancy
Item
Malignancy, except basal skin cell carcinoma
boolean
C0006826 (UMLS CUI [1])
bleeding disorder
Item
Known bleeding disorder (e.g., dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrands disease, DIC, fibrinogen deficiency, clotting factor deficiency)
boolean
C3251812 (UMLS CUI [1])
Pregnant or lactating
Item
Of childbearing potential with a positive urine or serum pregnancy test, pregnant, or lactating. A blood pregnancy test must have been performed within 3 days prior to the first treatment day. If performed on the same day, the result of a urine dipstick test may be used instead.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
Major systemic disease
Item
Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety
boolean
C0442893 (UMLS CUI [1])
Low platelet count
Item
Most recent platelet count < the LLN of the evaluating laboratory, or patients with suspicion of incipient ITP
boolean
C0040034 (UMLS CUI [1])
Low CD4, CD8 or CD 19
Item
CD4+, CD8+, or CD19+ ≤50 cells/microliter (ie, absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3); if abnormal cell count(s) subsequently rises above 50, eligibility may be reassessed
boolean
C0003323 (UMLS CUI [1])
C2698600 (UMLS CUI [2])
C2698589 (UMLS CUI [3])
Low Neutrophil cell count
Item
Neutrophil cell count ≤1000 cells/microliter; if abnormal cell count subsequently rises above 1000 cells/microliter, eligibility may be reassessed
boolean
C0853697 (UMLS CUI [1])
Other illness
Item
Any other illness or infection (latent or active) that, in the Investigator’s opinion, could be exacerbated by alemtuzumab
boolean
C3843746 (UMLS CUI [1])
Item
Treatment with immunosuppressive or antineoplastic drugs
text
C0021081 (UMLS CUI [1])
Criteria for Treatment Deferral: No 11 yes/no
Code List
Treatment with immunosuppressive or antineoplastic drugs
CL Item
yes (1)
CL Item
no (0)
No Criteria for Treatment Deferral
Item
Is the patient free of the above listed deferral criteria?
boolean
C0205421 (UMLS CUI [1])
Comment Treatment deferral
Item
Comment Treatment deferral
text
C0205421 (UMLS CUI [1,1])
C0947611 (UMLS CUI [1,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video